Level of heavy chains of neurofilaments, amyloids 1-40 and 1-42 in cerebrospinal fluid of patients with opticomyelitis and multiple sclerosis

Neuromyelitis optica (NMO) can lead to persistent disability in a short period of time. Persistent neurological deficit in demyelinating disorders is determined by neurodegeneration. As has been shown earlier neurodegeneration is characterized by changes in enzymes activity and shifts in b- amyloid levels. The aim of our study was try to check are there any difference in neurodegeneration of NMO and Multiple Sclerosis (MS) according to b-amyloid 1-40 and 1-42 levels in cerebrospinal fluid. Method. B-amyloids 1-40 and 1-42 were measured by an enzyme-linked immunosorbent assay in patients with MS (n = 52), NMO (n = 5) and control group (n = 26). Results. There was not any difference between NMO and MS (exacerbation). Level of b-amyloid 1-42 was higher in MS remission group than in NMO, but the same difference was detected between remission and exacerbation MS groups.

neurofilament, amyloid, neurodegeneration, demyelinating diseases, neuromyelitis optica, multiple sclerosis, cerebrospinal fluid

1. Wingerchuk D. M., Lennon V. A., Pittock S. J. et al. Revised diagnostic criteria for neuromyelitis optica // Neurology.- 2006.- Vol. 66.- Р. 1485-1489.

2. Wingerchuk D. M., Banwell B., Bennett J.L et. al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. // Neurology. - 2015, Vol. 85 (2), p. 177-189.

3. Kira J. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: Astrocytopathy as a common denominator in demyelinating disorders // Journal of the Neurological Sciences 2011.- Vol. 311 - P. 69-77.

4. Frischer J. M., Bramow S., Dal-Bianco A., et.al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. // Brain. 2009.- Vol. 132.- P. 1175-1189.

5. Bjartmar C., Kinkel R. P., Kidd G. et.al. Axonal loss in normal-appearing white matter in a patient with acute MS. // Neurology. 2001.- Vol. 57 (7).- P. 1248-1252.

6. De Stefano N., Matthews P.M., Fu L. et. al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. // Brain. 1998.- Vol. 121 (8).- P. 1469-77.

7. Valis M., Talab R., Stourac P. et. al. Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients. // Neuro Endocrinol Lett. 2008.-Vol. 29 (6).- P. 971-976.

8. Jiang K., Hein N., Eckert K. et. al. Regulation of the MAD 1 promoter by G-CSF. // Nucleic Acids Res. 2008.- Vol. 36 (5).- P. 1517-1131

9. Sladkova V., Mares J., Lubenova B. et. al. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome. // Neurol Res. 2011.- Vol. 33 (4).- P. 415-420.

10. Lennon V., Wingerchuk D., Kryzer T. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis // Lancet. - 2004.- Vol. 364.- Р. 2106-2112.

11. Wingerchuk D.M., Lennon V. A., Lucchinetti C. F. et. al. The spectrum of neuromyelitis optica // Lancet Neurol.-2007.- Vol. 6.-P. 805-15.